Why does cancer sometimes recur even after successful treatment, or why do some bacteria survive despite the use of powerful ...

Up to $54.3 million CEPI investment aims to help advance Moderna’s H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic ...

Having already claimed a win for the phase 2 study of its seizure drug, Praxis Precision Medicines is hoping fresh efficacy data will form the backbone of an approval application for the sodium ...

Send this article to your social connections.

Synopsys is well-positioned for growth, leveraging AI-powered EDA and the Ansys acquisition to drive innovation in chip design and verification. SNPS's strong financial performance, consistent revenue ...

NEW ORLEANS — Rouses Markets announced Thursday that it will begin phasing out pennies as the United States winds down production of the one-cent coin. The grocery chain says once each store’s penny ...

The transaction was a buy and now represents 1.19% of E. Ohman J:or Asset Management AB’s reportable U.S. equity assets as of September 30, 2025. Top holdings after the filing: MSFT: $396.72 million ...

The public will get a chance to provide input to regulators on a Lancaster city data center's proposed second phase, a two-story building expected to total 735,128 square feet and cost as much as $2.5 ...

CARMEL, Ind. – The Level Up 31 project aimed at improving U.S. 31 and I-465 in Hamilton County is underway–and that means the morning commute looks a little different. The Indiana Department of ...

Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in ...

HONOLULU (KHON2) — The second phase of Skyline has taken two years and three months, and it’s finally ready to open, with many expecting big changes to their commute. Skyline stations transform into ...

Metsera, Inc. (NASDAQ:MTSR) on Tuesday released topline data from VESPER-1 and data from a planned interim analysis for tolerability of VESPER-3 – two Phase 2b trials of MET-097i with potential for ...